Drugmaker AbbVie warned it will post a $3.5 billion impairment charge related to last year's $8.7 billion bet on Cerevel Therapeutics following the failure of the deal's key drug candidate, a ...
Michele Buck, a 20-year veteran of Hershey who assumed leadership in 2017, said she would step down from her roles as president and chief executive on June 30, 2026. The merger combines two of the ...
Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate initiatives; ‘EVERYBODY WANTS TO BE MY FRIEND!!!’ ...
AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...
Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...
The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...
AbbVie (NYSE:ABBV) said it expects to record an impairment charge of approximately $3.5B related to the drug emraclidine, ...
In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the ...
AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s ...
The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...
Dec. 11, 2024 — Investigators who previously found that a daily statin pill helps prevent heart attacks and strokes in people with HIV have now discovered a potential mechanism that may help to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback